Dementia
8 drugs3,327 FAERS reportsMedDRA PT
GET
/api/v1/reaction/dementiaReference statistics only. FAERS reports are voluntarily submitted and are not incidence rates, safety signals, or causal evidence. The drugs below are ranked by how often this reaction appears on FAERS reports for each drug — high share does not mean the drug caused the reaction, and absence from this list does not mean the reaction never occurred. This is not a symptom checker.
DefinitionNLM MeSH D003704
An acquired organic mental disorder with loss of intellectual abilities of sufficient severity to interfere with social or occupational functioning. The dysfunction is multifaceted and involves memory, behavior, personality, judgment, attention, spatial relations, language, abstract thought, and other executive functions. The intellectual decline is usually progressive, and initially spares the level of consciousness.
Drugs reporting Dementia (8)
Share = reports listing this reaction ÷ total matched reports for the drug. — means the upstream totals query failed at ingest and the denominator is unknown.
- 1Klebsiella Pneumoniae1100%
- 2Diethyltoluamide19.1%
- 3Aluminum Acetate25.0%
- 4Sulconazole14.5%
- 5Rivastigmine5673.0%
- 6Donepezil1,0953.0%
- 7Pimavanserin1,3152.5%
- 8Memantine3452.5%
Related reactions
Other reactions most often co-reported on the same drug set. Ranked by Jaccard similarity over drug-id sets — pure data-derived co-occurrence, not a clinical relationship.
Literature
Recent PubMed references pinned to Dementia as a MeSH major topic. About the reaction term itself — not about any specific drug.
- Erythrina caffra extract restores memory, modulates cholinergic dysfunction, neuroinflammation, and attenuates oxidative stress in cadmium-induced alzheimer's disease-like pathology in rats.Molecular biology reports · 2026 · Ed-Day S, Kacimi FE, El Gui R, et al.PMID 42207225DOI 10.1007/s11033-026-12036-x
- Lipid metabolic regulation of neuroinflammation in Alzheimer's disease.Frontiers in immunology · 2026 · Li T, Guo K, Ma Y, et al.PMID 42206051DOI 10.3389/fimmu.2026.1815719
- Scalable markers for early cognitive decline: Plasma p-tau217, subjective cognitive concerns, and digital testing: Results from the A4/LEARN studies.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026 · Khorsand B, Teichrow D, Ghanbarian E, et al.PMID 42204876DOI 10.1002/alz.71505
- Four decades of Alzheimer's disease discoveries, data, and research resources: The NIH Alzheimer's Disease Research Center Program.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026 · Donley G, Hsiao J, Balintfy J, et al.PMID 42204869DOI 10.1002/alz.71511
- Recommendations for genetic counseling for individuals at risk of autosomal dominant Alzheimer's disease in Latin America.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026 · Jiménez DA, Bagnati PM, Flores-Montes RE, et al.PMID 42204862DOI 10.1002/alz.71502
- Exploring the experiences and needs in everyday life of spouse carers of persons with dementia.International journal of qualitative studies on health and well-being · 2026 · Johansson MF, Marmstål Hammar L, Dahlberg L, et al.PMID 42204836DOI 10.1080/17482631.2026.2680726
Note. FAERS reports are voluntarily submitted and are NOT incidence rates, signals, or causal evidence. Counts reflect reporting volume, not how often a reaction occurs. Reference statistics only.